Effects of silver nanoparticles coated with anti-HER2 on irradiation efficiency of SKBR3 breast cancer cells

IET Nanobiotechnol. 2019 Oct;13(8):808-815. doi: 10.1049/iet-nbt.2018.5258.

Abstract

Breast cancer is the second cause of death in the world. Ionising radiation is a potent mutagen that can cause DNA damage, chromosomes breakage, and cell death. In the present study, radiotherapy and nanoparticle-antibodies (ABs) have been combined to enhance the efficacy of cancer cell treatment. Silver nanoparticles (SNP) were synthesised, coated with anti-HER2, and then characterised with different techniques such as X-ray diffraction, dynamic light scattering, transmission electron microscopy, Fourier transform infrared, and UV-Vis spectroscopy. SKBR3 cells were irradiated with cobalt-60 in the presence of nanoparticle-AB as the drug. Cell viability was measured using the diphenyltetrazolium bromide assay, and the cellular status was assessed by Raman spectroscopy. Irradiation considerably decreased cell viability proportionate to the dose increase and post-irradiation time. The surface-enhanced Raman spectroscopy increased the signal in the presence of SNP. Increasing the dose to 2 Gy increased the irradiation resistance, and higher dose increases (4 and 6 Gy) enhanced the irradiation sensitivity. Moreover, the cellular changes induced by irradiation in the presence of the drug were stable after 48 h. The authors results introduced the combination of the drug with radiation as an effective treatment for cancer and Raman spectroscopy as a suitable tool to diagnose effective irradiation doses.

Publication types

  • Retracted Publication

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / pathology
  • Breast Neoplasms / radiotherapy*
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Cell Survival / radiation effects
  • Coated Materials, Biocompatible / pharmacology*
  • Coated Materials, Biocompatible / therapeutic use
  • Drug Screening Assays, Antitumor
  • Dynamic Light Scattering
  • Female
  • Gamma Rays / therapeutic use
  • Humans
  • Materials Testing
  • Metal Nanoparticles / chemistry*
  • Radiation Tolerance / drug effects*
  • Radiation-Sensitizing Agents / chemical synthesis
  • Radiation-Sensitizing Agents / chemistry
  • Radiation-Sensitizing Agents / pharmacology
  • Radiation-Sensitizing Agents / therapeutic use
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Silver / chemistry*
  • Silver / pharmacology
  • Spectrum Analysis, Raman
  • Trastuzumab / chemistry
  • Trastuzumab / pharmacology*
  • Trastuzumab / therapeutic use
  • X-Ray Diffraction

Substances

  • Antineoplastic Agents
  • Coated Materials, Biocompatible
  • Radiation-Sensitizing Agents
  • Silver
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab